Current Issue February 2012, Vol. 34, No. 2 |
Looking for a publishing partner?
Go with the expert. For over 30 years, Clinical Therapeutics has been a leading journal voice for recent developments in drug therapy and pharmaceutical economics, serving an international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings.
Reap the rewards. As an author, Clinical Therapeutics affords you and your paper an unmatched array of benefits including:
- high-quality, rapid peer review;
- professional editorial staff whose goal is to guide you through the submission, review, and revision processes;
- rapid publication of your paper online, within 20 business days after acceptance;
- indexing by all major biomedical abstracting databases;
- strong annual and 5-year impact factors;
- inclusion in Science Direct, serving over 11 million users.
Get results. Submit your paper to Clinical Therapeutics online @ ees.elsevier.com/clinther
Issue Highlights
Pharmacotherapy
New Drug Review
-
Velaglucerase Alfa for the Management of Type 1 Gaucher DiseaseFebruary 2012(Vol. 34 | No. 2 | Pages 259-271)
Review Articles
-
Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid LeukemiaFebruary 2012(Vol. 34 | No. 2 | Pages 272-281)
-
A Network Meta-Analysis on the Efficacy of Serotonin Type 3 Receptor Antagonists Used in Adults During the First 24 Hours for Postoperative Nausea and Vomiting ProphylaxisFebruary 2012(Vol. 34 | No. 2 | Pages 282-294)
-
Pazopanib for the Treatment of Metastatic Renal Cell Carcinoma20 February 2012
-
A Randomized, Open-Label, 5-Period, Balanced Crossover Study to Evaluate the Relative Bioavailability of Eltrombopag Powder for Oral Suspension (PfOS) and Tablet Formulations and the Effect of a High-Calcium Meal on Eltrombopag Pharmacokinetics When Administered With or 2 Before or After PfOS16 February 2012
